Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 151 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Iacobucci G. Sixty seconds on . . . the RECOVERY trial. BMJ 2020;369:20 de abril. [Ref.ID 103597]
2. Cita con resumen
Joy TR, Monjed A, Zou GY, Hegele RA, McDonald ChG, Mahon JL. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014;160:301-10. [Ref.ID 97263]
3. Cita con resumen
Ruokoniemi P, Sund R, Arffman M, Helin-Salmivaara A, Huupponen R, Keskimäki I, Vehko T, Korhonen MJ. Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Findland. BMJ Open 2014;4:e005402. [Ref.ID 97211]
4.Tiene citas relacionadas Cita con resumen
Reith C, Landray M, Califf RM. Randomized clinical trials - Removing obstacles. N Engl J Med 2013;369:2269. [Ref.ID 96620]
5.Tiene citas relacionadas Cita con resumen
Galbraith KL. Randomized clinical trials - Removing obstacles. N Engl J Med 2013;369:2268-9. [Ref.ID 96619]
6.
Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, Califf RM, Collins R, Yusuf S. Randomized clinical trials - Removing unnecessary obstacles. N Engl J Med 2013;369:1061-5. [Ref.ID 96099]
7.Tiene citas relacionadas Cita con resumen
Evans SJW. An agenda for UK clinical pharmacology: pharmacoepidemiology. Br J Clin Pharmacol 2012;73:973-8. [Ref.ID 93098]
8.Enlace a cita original Cita con resumen
9. Cita con resumen
Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment. A randomized trial. Ann Intern Med 2011;155:87-96. [Ref.ID 91391]
10.
Brotons C. ¿Podemos mejorar la implementación de las guías de práctica clínica?. Aten Primaria 2009;41:246-7. [Ref.ID 86055]
11. Cita con resumen
Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61. [Ref.ID 84722]
12.Tiene citas relacionadas Cita con resumen
Vandenbroucke JP. What is the best evidence for determining harms of medical treatment?. Can Med Assoc J 2006;174:645-6. [Ref.ID 84676]
13.Tiene citas relacionadas Cita con resumen
Papanikolaou PN, Christidi GD, Ioannidis JPA. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. Can Med Assoc J 2006;174:635-41. [Ref.ID 84675]
14. Cita con resumen
Ibáñez L, Vidal X, Laporte JR. Proton pump inhibitors and risk of upper gastrointestinal bleeding in NSAID users. The American Journal of Gastroenterology 2008;103:2658-1659. [Ref.ID 84102]
15. Cita con resumen
Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O, on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008;371:1999-2012. [Ref.ID 83251]
16.Tiene citas relacionadas Cita con resumen
Vonnegut M. Is quality improvement improving quality? A view from the doctor's office. N Engl J Med 2007;357:2652-3. [Ref.ID 81931]
17.Tiene citas relacionadas Cita con resumen
Milstein A, Lee TH. Comparing physicians on efficiency. N Engl J Med 2007;357:2649-52. [Ref.ID 81930]
18. Cita con resumen
Anónimo. Second-generation antidepressants similarly effective, US study finds. Scrip 2007;3230:20. [Ref.ID 79138]
19.Tiene citas relacionadas Cita con resumen
D'Agostino Jr RB, D'Agostino Sr RB. Estimating treatment effects using observational data. JAMA 2007;297:314-6. [Ref.ID 78932]
Seleccionar todas
 
 1 a 20 de 151 siguiente >>